Group 1 - The core viewpoint is that the expectation of a Federal Reserve interest rate cut is boosting sentiment in the pharmaceutical sector, with the Medical Innovation ETF (516820.SH) rising by 1.04% [1] - Key stocks such as Haisco (002653), Baili Tianheng (688506), and Kanghong Pharmaceutical (002773) saw significant increases of 4.86%, 3.97%, and 3.91% respectively [1] - The U.S. July core CPI rose by 0.3%, slightly exceeding expectations, while inflation for tariff-sensitive goods remained moderate, reinforcing the expectation of a 25 basis point rate cut in September [1] Group 2 - Longjiang Securities noted that despite the typical vacation period for overseas pharmaceutical executives in July and August, there has been a notable acceleration in overseas expansion, with Chinese innovative drugs reaching $30 billion in exports in just one and a half months [2] - The acceleration in overseas expansion is attributed to pressures in the overseas industry and an increase in the "new" content of domestic innovative drugs [2] - The expectation of a weaker U.S. economy and employment data is likely to accelerate the pace of Federal Reserve rate cuts, enhancing global liquidity and benefiting technology stocks, which may provide an opportunity for investors to capitalize on the rebound in core pharmaceutical assets through the Medical Innovation ETF (516820) [2]

近日，恒生港股通创新药指数新编制方案正式生效，明确剔除CXO企业，聚焦创新药企，成为ETF 跟踪指数中首批"纯度"达100%的创新药指数。回测显示，此次调整后，该指数自2023年7月10日发布以 来年化收益率和夏普比率均更高。恒生创新药ETF（159316）是市场上唯一跟踪该指数的产品，可助力 投资者精准把握行业发展趋势。 每日经济新闻 港股创新药今日迎来回暖，信达生物、锦欣生物、百济神州等股走强，截至9:40，恒生港股通创新 药指数上涨1.1%，恒生创新药ETF（159316）成交额突破5000万元。截至昨日，该产品连续4个交易日 获资金加仓，最新规模达11.6亿元、再创成立以来新高。 昨日，国家医保局公示了通过商保创新药目录调整初步形式审查的121个药品通用名。从药品种类 看，以单抗注射液为代表的靶向药物是申报的主力军，其中PD-（L）1单抗的申报数量最多，涉及国内 上市公司包括乐普生物、恒瑞医药、复宏汉霖、中国生物制药等。 中信证券表示，下半年围绕创新驱动和国际化+自主可控+院外营销模式改革三个领域进行布局， 尤其是最具贝塔效应的创新药领域，长期坚定看好创新药板块，持续建议关注创新药领域的核心标的。 （ ...